Sandoz: Growth Hormone Biosimilar Efficacy Is Same As Forerunner
This article was originally published in PharmAsia News
Executive Summary
Sandoz Japan announced the approval of additional indications of Prader-Willi Syndrome short stature without epiphyseal line occlusion and SGA short stature for its growth hormone biosimilar Sandoz on Aug. 22, meaning the drug now has the same approved efficacy as its forerunner drug.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.